Ardelyx (United States)

Recent papers from Ardelyx (United States)

1. Treatment Satisfaction with Tenapanor: Real-World Survey of Patients with End-Stage Renal Disease and HyperphosphatemiaPatient Preference and Adherence · 2026
2. Patient Experience, Gender, Age, Race, and Social Determinants of HealthGastroenterology · 2026
3. Tenapanor is associated with earlier and sustained symptom relief in IBS-C: a post hoc analysisTherapeutic Advances in Gastroenterology · 2026
4. The role of serum phosphate control in supporting transplant readiness in patients on dialysisCurrent Medical Research and Opinion · 2025
5. Tenapanor Improves Abdominal Symptoms Irrespective of Changes in Complete Spontaneous Bowel Movement Frequency in Adults with Irritable Bowel Syndrome with ConstipationDigestive Diseases · 2024
6. A randomized pilot study to evaluate the stability, taste, and palatability of a novel liquid formulation of tenapanorDrug Development and Industrial Pharmacy · 2024
7. Review of the Patient Burden and Therapeutic Landscape of Irritable Bowel Syndrome with Constipation in the United StatesClinical and Experimental Gastroenterology · 2024
8. Tenapanor: A Phosphate Absorption Inhibitor for the Management of Hyperphosphatemia in Patients With Kidney FailureJournal of Renal Nutrition · 2024
9. Intestinal Permeability, Irritable Bowel Syndrome with Constipation, and the Role of Sodium-Hydrogen Exchanger Isoform 3 (NHE3)Clinical and Experimental Gastroenterology · 2024
10. An Overview of the Effects of Tenapanor on Visceral Hypersensitivity in the Treatment of Irritable Bowel Syndrome with ConstipationClinical and Experimental Gastroenterology · 2024
11. Tenapanor as Therapy for Hyperphosphatemia in Maintenance Dialysis Patients: Results from the OPTIMIZE StudyKidney360 · 2024
12. Abdominal Symptom Improvement During Clinical Trials of Tenapanor in Patients With Irritable Bowel Syndrome With Constipation: A Post Hoc AnalysisThe American Journal of Gastroenterology · 2024
13. NHE3 inhibitor tenapanor maintains intestinal barrier function, decreases visceral hypersensitivity, and attenuates TRPV1 signaling in colonic sensory neuronsAJP Gastrointestinal and Liver Physiology · 2024
14. Tenapanor Improves Long-Term Control of Hyperphosphatemia in Patients Receiving Maintenance Dialysis: the NORMALIZE StudyKidney360 · 2023
15. Long‐term safety of tenapanor in patients with irritable bowel syndrome with constipation in the T3MPO ‐3 studyNeurogastroenterology & Motility · 2023
16. Discovery of Tenapanor: A First-in-Class Minimally Systemic Inhibitor of Intestinal Na⁺/H⁺ Exchanger Isoform 3ACS Medicinal Chemistry Letters · 2022
17. Novel Treatments from Inhibition of the Intestinal Sodium–Hydrogen Exchanger 3International Journal of Nephrology and Renovascular Disease · 2021
18. Safety and Efficacy of Tenapanor for Long-term Serum Phosphate Control in Maintenance Dialysis: A 52-Week Randomized Phase 3 Trial (PHREEDOM)Kidney360 · 2021
19. Ursolic Acid and Related Analogues: Triterpenoids with Broad Health BenefitsSHILAP Revista de lepidopterología · 2021
20. A Randomized Trial of Tenapanor and Phosphate Binders as a Dual-Mechanism Treatment for Hyperphosphatemia in Patients on Maintenance Dialysis (AMPLIFY)Journal of the American Society of Nephrology · 2021